Press Release: 17 July 2017: UDG Healthcare plc (“the Group”), a leading international healthcare services provider, is pleased to announce the acquisition of Cambridge BioMarketing LLC, a US-based healthcare communications business, for a total consideration of up to $35m.
Cambridge BioMarketing is an industry leader in orphan and rare disease drug launches, a fast-growing area of drug development and commercialisation. The orphan drug and rare disease market is forecasted to grow by a CAGR of 11% between 2017 and 2022 to $209bn, with orphan drugs estimated to account for 21.4% of prescription sales by 20221. Cambridge BioMarketing also has a strong creative and digital function in a market where digital content is becoming increasingly important for pharmaceutical companies.